Developing low carbon salbutamol MDI: assessment of relative bioavailability of salbutamol with propellant HFA-152a - Amsterdam 2025

Breakthroughs in airway disease therapeutics: beyond biologics

Chair(s): Matteo Bonini, Andriana Papaioannou

Session type: Oral presentation

Developing low carbon salbutamol MDI: assessment of relative bioavailability of salbutamol with propellant HFA-152a

Christer Janson

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Safety, pharmacokinetics and pharmacodynamics of KT-621, an oral STAT6 degrader, in healthy adults

Arsalan Shabbir

Replay

Poster

Abstract

Slides

TETRIS: A 24-month, prospective study to observe clinical outcomes in COPD patients with different treatment journeys in Germany

Gernot G.u. Rohde

Replay

Poster

Abstract

Slides

Gene modules linked to ICS-induced lung function improvement in COPD: Insights from the GLUCOLD study

Jing Zhang

Replay

Poster

Abstract

Slides

Effect of mucoactive drugs on immunological parameters in patients with stable COPD

Dmytro Dobrianskyi

Replay

Poster

Abstract

Slides

Ensifentrine synergistically relaxes hyperreactive human bronchi from COPD donors in combination with ICS, LABA, and LAMA

Paola Rogliani

Replay

Poster

Abstract

Slides

Impact of inhaled triple therapy on symptomatic tobacco-exposed individuals with normal spirometry

Anna Salina

Replay

Abstract

Slides

Relationship between repeated sputum and blood eosinophil counts in COPD.

Dave Singh

Replay

Poster

Abstract

Slides

The effect of heme and bacteria on endothelial barrier function in COPD.

James Baker

Replay

Abstract

Slides

Developing low carbon salbutamol MDI: assessment of relative bioavailability of salbutamol with propellant HFA-152a

Christer Janson

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}